What is Sertraline? Understanding Its Uses, Dosage, and Side Effects

Sertraline is a widely prescribed medication categorized as a selective serotonin reuptake inhibitor (SSRI). It plays a crucial role in managing a range of mental health conditions, making it a cornerstone in psychiatric treatment. This article delves into the specifics of sertraline, exploring its approved and off-label uses, how it functions in the brain, proper administration, potential adverse effects, contraindications, and essential monitoring parameters. Understanding these aspects is vital for both healthcare professionals and individuals seeking information about this medication.

Sertraline: FDA-Approved and Off-Label Uses

Sertraline is approved by the Food and Drug Administration (FDA) for the treatment of several mental health disorders. Its efficacy in these conditions has been well-established through extensive clinical research.

FDA-Approved Indications:

• Major Depressive Disorder (MDD): Sertraline is a first-line treatment for major depressive disorder, a condition characterized by persistent sadness, loss of interest, and other emotional and physical symptoms that significantly impair daily functioning.[1]
• Obsessive-Compulsive Disorder (OCD): This anxiety disorder involves intrusive, unwanted thoughts (obsessions) and repetitive behaviors (compulsions). Sertraline helps reduce the severity of obsessions and compulsions, improving quality of life for individuals with OCD.[2]
• Panic Disorder (PD): Panic disorder is marked by sudden, unexpected panic attacks, characterized by intense fear and physical symptoms like rapid heartbeat and shortness of breath. Sertraline aids in decreasing the frequency and intensity of these attacks.[3]
• Post-Traumatic Stress Disorder (PTSD): PTSD can develop after experiencing or witnessing a traumatic event. Sertraline assists in managing symptoms such as flashbacks, nightmares, and severe anxiety associated with trauma.[4]
• Premenstrual Dysphoric Disorder (PMDD): PMDD is a severe form of premenstrual syndrome (PMS), causing significant mood disturbances and physical symptoms in the days leading up to menstruation. Sertraline can alleviate these symptoms, whether taken daily or intermittently during the luteal phase of the menstrual cycle.
• Social Anxiety Disorder (SAD): Also known as social phobia, social anxiety disorder involves intense fear of social situations and scrutiny by others. Sertraline helps reduce anxiety and fear in social settings, enabling individuals to participate more comfortably in daily life.

Non-FDA-Approved (Off-Label) Indications:

While FDA-approved for specific conditions, sertraline is also used off-label to treat other disorders where evidence suggests potential benefit. Off-label use means the medication is prescribed for a condition not specifically approved by the FDA, but based on clinical judgment and available research.

• Binge Eating Disorder: Sertraline may help reduce the frequency of binge eating episodes in individuals with binge eating disorder, an eating disorder characterized by recurrent episodes of consuming large amounts of food in a short period, accompanied by a sense of lack of control.[5]
• Body Dysmorphic Disorder (BDD): BDD is characterized by a preoccupation with perceived flaws in physical appearance, causing significant distress and impairment. Sertraline can help manage the anxiety and obsessive thoughts associated with BDD.
• Bulimia Nervosa (BN): Although primarily treated with other therapies, sertraline may be used as part of a comprehensive treatment plan for bulimia nervosa, an eating disorder involving cycles of binge eating and compensatory behaviors like purging.[5]
• Generalized Anxiety Disorder (GAD): GAD involves excessive worry and anxiety about various aspects of life. Sertraline can be effective in reducing overall anxiety levels in individuals with GAD.
• Premature Ejaculation: In some cases, sertraline is used to treat premature ejaculation, a common sexual dysfunction in men.

How Sertraline Works: Mechanism of Action

Sertraline’s therapeutic effects stem from its mechanism of action as a selective serotonin reuptake inhibitor (SSRI). To understand this, it’s helpful to know a bit about neurotransmitters. Neurotransmitters are chemical messengers in the brain that transmit signals between nerve cells (neurons). Serotonin is one such neurotransmitter, playing a vital role in regulating mood, sleep, appetite, and other functions.

After serotonin is released into the synapse (the space between neurons) and transmits a signal, it is normally reabsorbed back into the presynaptic neuron – a process called reuptake. SSRIs like sertraline work by selectively blocking the reuptake of serotonin in the brain. By inhibiting this reuptake, sertraline increases the amount of serotonin available in the synapse. This enhanced serotonin availability is believed to improve mood, reduce anxiety, and alleviate symptoms of the conditions sertraline is used to treat.[1]

While sertraline’s primary action is on serotonin, studies suggest it also has some influence on dopamine, another neurotransmitter involved in mood and motivation. Research indicates that sertraline may increase dopamine levels in certain brain areas more than some other SSRIs. However, this effect is less pronounced than its impact on serotonin.[6, 7] The combined effect on serotonin and, to a lesser extent, dopamine contributes to sertraline’s effectiveness in treating a range of psychiatric disorders.

Sertraline Administration and Dosage

Sertraline is typically administered orally in tablet, capsule, or liquid solution form. It is usually taken once daily, either in the morning or evening. If drowsiness occurs, taking it in the evening might be preferable. Food can enhance sertraline absorption, so it can be taken with or without meals, but consistency with food intake is generally recommended.[8]

Available Dosage Forms:

• Tablets: 25 mg, 50 mg, 100 mg
• Capsules: 150 mg, 200 mg
• Solution: 20 mg/mL

Adult Dosage Guidelines:

Dosage varies depending on the condition being treated and individual patient factors. The following are general guidelines, and a healthcare provider will determine the most appropriate dose for each individual.

• Major Depressive Disorder and Obsessive-Compulsive Disorder:
  • Starting Dose: 50 mg once daily
  • Maintenance Dose: 50 to 200 mg orally once a day. Dosage adjustments are typically made gradually at weekly intervals based on clinical response.
• Premenstrual Dysphoric Disorder (PMDD):
  • Continuous Dosing (Every Day): Start at 50 mg once daily, with potential increases of 50 mg per menstrual cycle up to a maximum of 150 mg daily.
  • Intermittent Dosing (Luteal Phase Only): Begin with 50 mg once daily, increasing to 100 mg daily for the remainder of the dosing cycle if needed. Intermittent dosing starts 14 days before anticipated menstruation and continues until the end of menses, repeated with each cycle.
• Panic Disorder, Post-Traumatic Stress Disorder, and Social Anxiety Disorder:
  • Starting Dose: 25 mg once daily
  • Dosage Increase: Increased in 50 mg increments at weekly intervals to a maximum of 200 mg per day. Administration can be at any time of day.

Special Populations:

• Pregnancy: Sertraline is classified as a Category C medication by the American College of Obstetricians and Gynecologists. This means animal studies have shown adverse effects on the fetus, but there are no adequate and well-controlled studies in pregnant women. However, it is often considered one of the safer antidepressants to use during pregnancy when the benefits outweigh the risks.[10]
• Breastfeeding Women: Sertraline is generally considered a preferred antidepressant for breastfeeding mothers, as it passes into breast milk in relatively low amounts.[11]
• Hepatic Impairment: Patients with liver disease should use sertraline cautiously. Lower or less frequent doses may be necessary due to reduced metabolism of the drug.
• Renal Impairment: Dosage adjustments are generally not required for patients with kidney problems.

Sertraline Withdrawal:

Abruptly stopping sertraline, like other serotonergic antidepressants, can lead to withdrawal symptoms, also known as discontinuation syndrome. These symptoms can include nausea, sweating, mood changes, irritability, dizziness, sensory disturbances (like electric shock sensations), tremor, anxiety, confusion, headache, fatigue, sleep disturbances, and in rare cases, hypomania or seizures. To minimize withdrawal effects, it is crucial to gradually reduce the dosage under medical supervision rather than stopping suddenly.

Sertraline Side Effects

While generally well-tolerated, sertraline, like all medications, can cause side effects. SSRIs are typically better tolerated than older classes of antidepressants, such as tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs).

Common Side Effects:

Common side effects of sertraline may include:[7]

• Nausea
• Diarrhea
• Dry mouth (xerostomia)
• Sweating
• Dizziness
• Lightheadedness or syncope
• Somnolence (drowsiness) or insomnia
• Tremor
• Fatigue
• Sexual dysfunction (such as decreased libido, erectile dysfunction, ejaculation disorder in men, and sexual disorder in women)
• Confusion
• Hallucinations (less common)
• Rhinitis (nasal inflammation)

Serious Side Effects and Risks:

• Bleeding Risk: Sertraline can increase the risk of bleeding because it can inhibit platelet aggregation (the clumping of blood cells to form clots). This risk may be higher when used with other medications that also increase bleeding risk, such as aspirin, NSAIDs (like ibuprofen or naproxen), and anticoagulants (like warfarin).[20]
• QT Prolongation: Sertraline can cause a dose-dependent, but generally modest, prolongation of the QT interval on an electrocardiogram (ECG). QT prolongation is a heart rhythm abnormality that can, in rare cases, lead to serious arrhythmias. The risk of QT prolongation is considered lower with sertraline compared to some other SSRIs like citalopram.[12]
• Serotonin Syndrome: This is a potentially life-threatening condition that can occur when there is too much serotonin activity in the brain and body. It is more likely to happen when sertraline is combined with other serotonergic medications, such as other antidepressants, certain pain medications, or St. John’s Wort. Symptoms can range from mild to severe and include agitation, confusion, muscle twitching (myoclonus), muscle rigidity, sweating, tremor, overactive reflexes (hyperreflexia), dilated pupils, diarrhea, headache, shivering, goosebumps, and fever (hyperthermia). Severe cases can involve high fever, seizures, irregular heartbeat, and unconsciousness.[13, 25]
• Increased Risk of Suicidal Thoughts and Behavior: Like other antidepressants, sertraline carries a black box warning regarding an increased risk of suicidal thoughts and behavior in children, adolescents, and young adults (up to age 24) with major depression and other psychiatric disorders. It is crucial to monitor patients, especially at the start of treatment and during dosage changes, for worsening depression, suicidal ideation, or unusual behavior changes.
• Hyponatremia (Low Sodium Levels): Sertraline, particularly in older adults, can sometimes lead to hyponatremia, a condition where sodium levels in the blood become dangerously low. This is often due to the syndrome of inappropriate antidiuretic hormone secretion (SIADH). Symptoms can include headache, nausea, vomiting, muscle cramps, confusion, and in severe cases, seizures and coma.[14, 15]
• Cardiovascular Malformations in Infants (with first-trimester use): Some studies suggest a slightly increased risk of certain heart defects, such as atrial and ventricular septal defects, in infants born to mothers who took sertraline during the first trimester of pregnancy.[16]
• Neonatal Complications (with third-trimester use): Newborns exposed to sertraline in the third trimester may experience withdrawal symptoms or other complications after birth, sometimes requiring prolonged hospitalization, feeding support, and respiratory assistance.

Sertraline Contraindications

Contraindications are specific situations where a medication should not be used because the risk outweighs any potential benefit. Sertraline is contraindicated in the following situations:

• Hypersensitivity: Patients with a known allergy or hypersensitivity to sertraline or any of its ingredients should not take it.
• Concurrent Use of MAOIs: Monoamine oxidase inhibitors (MAOIs) are another class of antidepressants. Combining sertraline with MAOIs, including linezolid (an antibiotic with MAOI properties) and methylene blue, is strictly contraindicated due to the high risk of serotonin syndrome. There should be a washout period of at least 14 days between discontinuing an MAOI and starting sertraline, and vice versa.[17]
• Concurrent Use with Thioridazine or Pimozide: Sertraline should not be used with thioridazine (an antipsychotic medication) or pimozide (another antipsychotic) due to the potential for serious heart rhythm problems (QT prolongation).
• Disulfiram (with Sertraline Solution): Sertraline oral solution contains alcohol. Therefore, it is contraindicated in patients taking disulfiram (Antabuse), a medication used to treat alcoholism, as it can cause an alcohol-disulfiram reaction.

Black Box Warning:

Sertraline carries a U.S. FDA black box warning regarding the increased risk of suicidal thoughts and behaviors in pediatric patients and young adults (ages 18 to 24). Close monitoring is essential in these age groups, especially when starting treatment or adjusting the dosage.[18]

Monitoring During Sertraline Treatment

Regular monitoring is crucial when taking sertraline to ensure effectiveness and safety. This includes monitoring for:

• Changes in Behavior and Suicidality: Patients, especially children, adolescents, and young adults, should be closely monitored for any unusual changes in behavior, worsening depression, anxiety, panic attacks, insomnia, irritability, agitation, hostility, impulsivity, akathisia (restlessness), hypomania, mania, or suicidal thoughts or behaviors. Monitoring is particularly important during the initial months of treatment and when dosages are changed.
• Mania or Hypomania: Sertraline can potentially trigger mania or hypomania in individuals with bipolar disorder or a predisposition to mania. Patients with a family history of bipolar disorder or mania should be monitored for symptoms like elevated mood, racing thoughts, decreased need for sleep, and impulsive behavior.
• Bleeding: Patients should be monitored for signs of abnormal bleeding, especially if they are also taking medications that increase bleeding risk. Symptoms to watch for include easy bruising, nosebleeds (epistaxis), and prolonged bleeding from cuts.
• Adverse Effects: Regularly assess for any side effects, and manage them appropriately.
• Withdrawal Symptoms: If discontinuing sertraline, monitor for withdrawal symptoms, especially if the medication is stopped abruptly. Gradual dose reduction is recommended to minimize these effects.
• Hyponatremia (in Elderly): Older adults are at higher risk for hyponatremia. Periodic monitoring of sodium levels may be recommended, especially in those at risk.
• QT Interval (in susceptible individuals): While the risk is relatively low, ECG monitoring of the QT interval may be considered in patients with pre-existing cardiac conditions or those taking other medications that prolong the QT interval.[21, 22]
• Pregnancy and Breastfeeding: In pregnant women treated with sertraline in the third trimester, physicians should consider tapering sertraline based on risk-benefit analysis to potentially minimize neonatal complications. Therapeutic drug monitoring may be considered during pregnancy and breastfeeding to ensure safety for both mother and infant, although it is not always mandatory.[23, 24]

Sertraline Toxicity and Overdose

Overdosing on sertraline alone is generally less likely to be fatal compared to older antidepressants. However, overdose can still be serious and require medical attention.

Symptoms of Sertraline Overdose:

Sertraline overdose can manifest in various symptoms, including:

• Nausea and vomiting
• Drowsiness
• Tremor
• Agitation
• Dizziness
• Rapid heartbeat (tachycardia)
• Electrocardiogram (ECG) abnormalities (e.g., QT prolongation)
• In rare cases, serotonin syndrome, seizures, and coma.

Treatment of Sertraline Overdose and Serotonin Syndrome:

Management of sertraline overdose focuses on supportive care and symptom management. In cases of serotonin syndrome due to overdose or drug interactions, the following measures may be taken:[25]

• Discontinuation of Sertraline and other Serotonergic Agents: Immediately stop sertraline and any other medications that may be contributing to serotonin syndrome.
• Supportive Care: Provide supportive measures such as intravenous fluids, oxygen, and monitoring of vital signs.
• Symptom Control:
  • Agitation: Benzodiazepines can be used to manage agitation and anxiety.
  • Nausea and Vomiting: Antiemetics (non-serotonergic) can help control nausea and vomiting.
  • Hyperthermia: Cooling measures, such as cooling blankets and ice packs, are essential to manage hyperthermia. Antipyretics (fever-reducing medications like acetaminophen) are generally not effective for hyperthermia caused by serotonin syndrome.
  • Muscle Rigidity and Tremor: Benzodiazepines can help reduce muscle rigidity and tremor. In severe cases with very high fever and muscle rigidity, neuromuscular paralysis and intubation with mechanical ventilation may be necessary.
• Serotonin Antagonists: In severe cases of serotonin syndrome, serotonin antagonists like cyproheptadine may be used to block serotonin activity.

Enhancing Healthcare Team Outcomes in Sertraline Therapy

Optimal patient outcomes with sertraline therapy rely on effective collaboration and communication among the interprofessional healthcare team. This team typically includes primary care physicians, psychiatrists, nurse practitioners, pharmacists, and other healthcare professionals.

Key Strategies for Enhanced Outcomes:

• Regular Patient Monitoring: All team members involved in patient care should participate in ongoing monitoring for symptom improvement, adverse effects, and medication adherence.
• Medication Knowledge: All providers should have a comprehensive understanding of sertraline’s indications, contraindications, adverse effects, and potential drug interactions.
• Patient Education: Educating patients and their families about sertraline is crucial. This includes information on expected benefits, potential side effects, the importance of adherence, and recognizing signs of toxicity or serotonin syndrome. Pharmacists play a vital role in reinforcing medication information and addressing patient questions.
• Dosing Adjustments and Special Populations: Healthcare professionals should be vigilant about considering appropriate dosing adjustments, particularly for elderly patients and those with hepatic impairment.
• Preventing Serotonin Syndrome and Polypharmacy: Clinicians should be cautious about prescribing multiple serotonergic medications concurrently to avoid serotonin syndrome. Pharmacists can contribute significantly by reviewing medication regimens, identifying potential drug interactions, and advising on appropriate dosing.
• Medication Reconciliation and Transitions of Care: During transitions of care, such as hospital discharge or changes in providers, careful medication reconciliation is essential to ensure continuity of safe and effective sertraline therapy.
• Nursing Role: Nurses are critical in monitoring patient compliance, providing patient education and counseling, assessing therapeutic effectiveness, being aware of potential adverse drug reactions, and communicating any concerns to the rest of the team.

By fostering a cohesive interprofessional approach, healthcare teams can optimize the therapeutic benefits of sertraline while minimizing potential risks and improving patient safety and outcomes in the management of various mental health conditions.

References

1. Cipriani A, La Ferla T, Furukawa TA, Signoretti A, Nakagawa A, Churchill R, McGuire H, Barbui C. Sertraline versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2010 Apr 14;(4):CD006117. [PMC free article: PMC4163971] [PubMed: 20393946]
2. Fenske JN, Schwenk TL. Obsessive compulsive disorder: diagnosis and management. Am Fam Physician. 2009 Aug 01;80(3):239-45. [PubMed: 19621834]
3. Hobgood CD, Clayton AH. Sertraline in the treatment of panic disorder. Drugs Today (Barc). 2009 May;45(5):351-61. [PubMed: 19584964]
4. Buhmann CB, Andersen HS. [Diagnosing and treating post-traumatic stress disorder]. Ugeskr Laeger. 2017 Jun 12;179(24) [PubMed: 28606295]
5. Aigner M, Treasure J, Kaye W, Kasper S., WFSBP Task Force On Eating Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. World J Biol Psychiatry. 2011 Sep;12(6):400-43. [PubMed: 21961502]
6. Kitaichi Y, Inoue T, Nakagawa S, Boku S, Kakuta A, Izumi T, Koyama T. Sertraline increases extracellular levels not only of serotonin, but also of dopamine in the nucleus accumbens and striatum of rats. Eur J Pharmacol. 2010 Nov 25;647(1-3):90-6. [PubMed: 20816814]
7. Sanchez C, Reines EH, Montgomery SA. A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike? Int Clin Psychopharmacol. 2014 Jul;29(4):185-96. [PMC free article: PMC4047306] [PubMed: 24424469]
8. Hicks JK, Bishop JR, Sangkuhl K, Müller DJ, Ji Y, Leckband SG, Leeder JS, Graham RL, Chiulli DL, LLerena A, Skaar TC, Scott SA, Stingl JC, Klein TE, Caudle KE, Gaedigk A., Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther. 2015 Aug;98(2):127-34. [PMC free article: PMC4512908] [PubMed: 25974703]
9. Preskorn SH, Lane RM. Sertraline 50 mg daily: the optimal dose in the treatment of depression. Int Clin Psychopharmacol. 1995 Sep;10(3):129-41. [PubMed: 8675965]
10. ACOG Committee on Practice Bulletins–Obstetrics. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstet Gynecol. 2008 Apr;111(4):1001-20. [PubMed: 18378767]
11. Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Nov 15, 2024. Sertraline. [PubMed: 30000250]
12. Beach SR, Kostis WJ, Celano CM, Januzzi JL, Ruskin JN, Noseworthy PA, Huffman JC. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. J Clin Psychiatry. 2014 May;75(5):e441-9. [PubMed: 24922496]
13. Duignan KM, Quinn AM, Matson AM. Serotonin syndrome from sertraline monotherapy. Am J Emerg Med. 2020 Aug;38(8):1695.e5-1695.e6. [PubMed: 31837902]
14. By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019 Apr;67(4):674-694. [PubMed: 30693946]
15. Varela Piñón M, Adán-Manes J. Selective Serotonin Reuptake Inhibitor-Induced Hyponatremia: Clinical Implications and Therapeutic Alternatives. Clin Neuropharmacol. 2017 Jul/Aug;40(4):177-179. [PubMed: 28622213]
16. Shen ZQ, Gao SY, Li SX, Zhang TN, Liu CX, Lv HC, Zhang Y, Gong TT, Xu X, Ji C, Wu QJ, Li D. Sertraline use in the first trimester and risk of congenital anomalies: a systemic review and meta-analysis of cohort studies. Br J Clin Pharmacol. 2017 Apr;83(4):909-922. [PMC free article: PMC5346877] [PubMed: 27770542]
17. Sola CL, Bostwick JM, Hart DA, Lineberry TW. Anticipating potential linezolid-SSRI interactions in the general hospital setting: an MAOI in disguise. Mayo Clin Proc. 2006 Mar;81(3):330-4. [PubMed: 16529136]
18. DeVane CL, Liston HL, Markowitz JS. Clinical pharmacokinetics of sertraline. Clin Pharmacokinet. 2002;41(15):1247-66. [PubMed: 12452737]
19. Leverich GS, Altshuler LL, Frye MA, Suppes T, McElroy SL, Keck PE, Kupka RW, Denicoff KD, Nolen WA, Grunze H, Martinez MI, Post RM. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry. 2006 Feb;163(2):232-9. [PubMed: 16449476]
20. Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry. 2010 Dec;71(12):1565-75. [PubMed: 21190637]
21. Glassman AH, O’Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT, Krishnan KR, van Zyl LT, Swenson JR, Finkel MS, Landau C, Shapiro PA, Pepine CJ, Mardekian J, Harrison WM, Barton D, Mclvor M., Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002 Aug 14;288(6):701-9. [PubMed: 12169073]
22. O’Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, Zakhary B, Stough WG, Arias RM, Rivelli SK, Krishnan R., SADHART-CHF Investigators. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol. 2010 Aug 24;56(9):692-9. [PMC free article: PMC3663330] [PubMed: 20723799]
23. Paulzen M, Goecke TW, Stickeler E, Gründer G, Schoretsanitis G. Sertraline in pregnancy – Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood. J Affect Disord. 2017 Apr 01;212:1-6. [PubMed: 28129551]
24. Pinheiro E, Bogen DL, Hoxha D, Ciolino JD, Wisner KL. Sertraline and breastfeeding: review and meta-analysis. Arch Womens Ment Health. 2015 Apr;18(2):139-146. [PMC free article: PMC4366287] [PubMed: 25589155]
25. Wang RZ, Vashistha V, Kaur S, Houchens NW. Serotonin syndrome: Preventing, recognizing, and treating it. Cleve Clin J Med. 2016 Nov;83(11):810-817. [PubMed: 27824534]